A study to assess whether factor VIII given once a week will prevent major bleeds in severe hemophilia A

Efficacy of once weekly prophylactic therapy in prevention of clinically significant bleeds in patients with severe Hemophilia A

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/12/005277

Enrollment

Registered

2014-12-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Children with Severe Hemophilia A

Interventions

Intervention1: Factor VIII ONCE a WEEK: Factor VIII is given at 20IU/kg intravenously once a week as prophylaxis to children with severe hemophilia A with the aim of preventing major bleeds.Total dura

Eligibility

Inclusion criteria

Inclusion criteria: children 1-12 years of age with severe hemophilia A and no detectable inhibitors are recruited to the study

Exclusion criteria

Exclusion criteria: children, whose parents do not give a written informed consent and children with any other bleeding diathesis are excluded from the study.

Design outcomes

Primary

Measure	Time frame
To assess the efficacy of once weekly factor VIII prophylaxis in the prevention of clinically significant bleeds in patients with severe Hemophilia ATimepoint: 18 months	—

Secondary

Measure	Time frame
To assess the efficacy of once weekly factor VIII prophylaxis in preserving the index joint structure in patients with severe Hemophilia ATimepoint: 18 months	—

Countries

India

Contacts

Public ContactDr T K Datta

JIPMER

tkduttajipmer@yahoo.co.uk09443602330

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026